Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2025

Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited-stage small-cell lung cancer: A retrospective, multi-center, real-world study.

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZichen ZhaoYanbian UniversityHRHao RongSichuan Cancer HospitalMLMengxia LiHuazhong Agricultural University

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals improved progression-free and overall survival in patients receiving neoadjuvant immunochemotherapy compared to chemotherapy and concurrent chemoradiotherapy.

Key Points

  • Neoadjuvant immunochemotherapy shows superior progression-free survival over chemotherapy and concurrent chemoradiotherapy.
  • The pathological complete response rate was significantly higher in the immunochemotherapy group compared to chemotherapy (35.7% vs. 7.1%).
  • Analysis included 139 treatment-naive patients, with 84 undergoing neoadjuvant therapy followed by surgery.
  • These findings support considering neoadjuvant immunochemotherapy in limited-stage small-cell lung cancer treatment.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/68d42047713b0b5dfea68c23https://doi.org/10.1002/ijc.70153
View Full Paper
Ask AI
Bookmark
Share